Background and Aims To reduce hepatitis C virus (HCV) transmission among people who inject drugs (PWID), Scottish
INTRODUCTION
Hepatitis C virus (HCV) is a blood-borne disease with a high global burden [1] , and a is leading cause of death and morbidity [2, 3] . It is estimated that 90% of HCV infections in Scotland are acquired through injecting drug use [4] , with people who inject drugs (PWID) harbouring a high burden of infection (54% seroprevalence in 2008/09 ) [5, 6] .
Evidence suggests that needle and syringe provision (NSP) and opioid substitution therapy (OST) can reduce an individual's risk of HCV acquisition [7] , but little evidence exists of their impact at the population level [8] [9] [10] [11] . Modelling has estimated the impact of these interventions on HCV transmission at the population level [12, 13] , as well as the impact of HCV treatment as prevention [14, 15] ; however, no analyses have validated their projections against epidemiological data.
In Scotland, NSP and OST were introduced in the 1980s, increasing incrementally since then, with their scale-up credited to decreasing HCV prevalence among PWID in the 1990s [16, 17] . However, HCV prevalence has remained high since then and new presentations for HCV-related liver failure/cancer have been increasing [4, 5] . Therefore, in 2008, the Scottish government launched a national action plan for HCV, aiming to reduce HCV transmission among PWID alongside reducing HCV-related morbidity. The strategy was underpinned by additional investment above existing HCV funding (~100 million during 2008-15) and focused on scalingup harm reduction interventions (particularly providing needle/syringes and other injecting equipment) and HCV testing/treatment services [4, 18] . Contemporaneously, the Scottish Government published a new drug and alcohol strategy, setting out a programme to tackle Scotland's drug problem and reduce waiting times for drug treatment, thus having the potential to impact the delivery of OST [19] . During the first 3 years of these strategies (2008/09 to 2011/12), the scale-up of high coverage needle and syringe provision (high coverage NSP-defined as exchanging at least one sterile needle/syringe per injection) increased by 40% [5] , OST coverage increased by 30% [5] and annual numbers of HCV treatments doubled to 1000 [4] , with almost half among current or temporarily ceased PWIDs (mainly on OST). Concurrently, a halving in HCV incidence occurred [5] . However, there was no control comparison for this nation-wide programme, so it is difficult to determine whether this decrease in HCV incidence occurred due to the intervention scale-up or would have occurred anyway. Similar issues have been addressed in the HIV field by using modelling to determine whether observed changes in disease transmission are consistent with the scale-up of specific interventions [11, [20] [21] [22] [23] [24] .
We modelled the transmission of HCV among PWID in Scotland using data from national cross-sectional surveys carried out between 2008 and 2014. A dynamic, deterministic model was implemented to capture all intervention components and behavioural changes, enabling us to quantify how they may have affected transmission. Using synthesized evidence on the efficacy of NSP and OST [7] , the model was used to test whether observed decreases in HCV incidence and prevalence among PWID from 2008-2015 were consistent with the scale-up of interventions during this period, and then quantify the impact of the national HCV and drug strategies that resulted in this scale-up. This dynamic transmission process is something that could not be tested with a statistical model.
METHODS

Model description
A dynamic, deterministic mathematical model of HCV transmission among PWID was developed. The PWID population was stratified into current (had injected in the previous year) and temporarily ceased (had not injected in the previous year) PWID. These groups were divided into short-term (< 1 year since onset), mid-term (1-9 years since onset) and long-term (≥ 10 years since onset) PWID, stratified into those on OST and high coverage NSP, as well as whether they were high risk (defined as either currently homeless or injecting stimulants) or not (Supporting information, Fig. S1a) . PWID enter the model through initiating injecting into the current, short-term injecting group, and leave through permanently ceasing injecting (from the temporarily ceased groups) or through drug-related or non-drugrelated mortality (all groups). All PWID enter the model with no coverage of OST or high-coverage NSP, with a time-varying proportion being high-or low-risk (see Model parameterization). PWID transition between different injecting, intervention and risk states at specified rates. All transitions are bidirectional, except for those between injecting durations. All current PWID can temporarily cease injecting (more likely if on OST), with these PWID then either leaving the model due to permanently ceasing injecting or returning to currently injecting status.
The model is also stratified by HCV infection status (Supporting information, Fig. S1b ), with all new PWID being susceptible to infection. The model simulates transmission of HCV among currently injecting PWID, with transmission occurring at a per-capita rate dependent on the injecting risk (high-risk or not), intervention status (OST and/or high coverage NSP) and duration of injecting (see Supporting information for further details). Once infected, PWID either transition to the chronically infected group or spontaneously clear infection, transitioning to the previously infected group. Due to uncertainty in the evidence [25] [26] [27] [28] [29] , we assume that previously infected PWID are re-infected with the same risk as for primary infections of susceptible PWID. Chronically infected individuals can be treated, whereupon they either attain a sustained viral response (SVR) and move to the previously infected group or transition to the treatment failure group. In the baseline model, treatment failures are not retreated. The model assumes that PWID mix to form transmission contacts, with a user-defined proportion of these contacts being formed randomly proportional to the overall transmission risk of PWID in different subgroups and the remainder being formed assortatively (like-with-like) with PWID of the same duration of injecting (short-term, mid-term or long-term) or risk level (high-or low-risk).
Model parameterization
The model was primarily parameterized and calibrated using data from four large surveys (n = 2194-3315 for each survey) undertaken among people who had ever injected drugs (~80% had injected in the previous 6 months), recruited from~100 (50% of all) sites providing injecting equipment across Scotland between 2008 and 2014: the Needle Exchange Surveillance Initiative (NESI) surveys [5, 6, 30] . Data analyses were undertaken using Stata version 14.2. Historical survey data, intervention output and PWID size estimation data were also incorporated as described below, with the data sources described in the Supporting information. [31] were used to estimate the proportion of PWID that were high-risk (defined by either being homeless during the past 6 months or currently injecting stimulants-both associated with increased HCV risk in the NESI data sets) for different durations of injecting. The prevalence of high-risk behaviours was greater in those with shorter rather than longer injecting durations, and so this was incorporated into the model.
Intervention parameters
OST coverage. We assumed that OST started in 1985, in response to the spread of HIV infection among PWID. Estimates of OST coverage among PWID in Scotland between 1995 and 2014 were derived from data on methadone prescriptions dispensed across Scotland [32] [33] [34] , and self-reported survey data on OST uptake from Glasgow (2005) [31] and the NESI surveys (Supporting information, Fig. S2a ). NESI data suggested higher OST coverage among those injecting for longer, which was incorporated into the model (Supporting information, Table S2 ).
NSP coverage. NSP coverage was estimated from the number of syringes distributed in Glasgow or nationally from 1988/89 to 2012/13 [5, [35] [36] [37] , estimates of the number of PWID in Scotland [38] and the average injecting frequency while accounting for differences by OST status (from NESI) and the changing coverage of OST (Supporting information, Fig. S2b ). Due to high NSP coverage across all injecting durations, we assumed the same coverage for all PWID.
HCV risk. Data from a UK pooled analysis were used to parameterize the degree to which being on OST, high coverage NSP or both reduces the risk of acquiring HCV [7, 39] . Using NESI, risk ratios were calculated for the increased risk of HCV acquisition associated with being homeless or injecting stimulants (denoted as high-risk, Supporting information, Table S1 ) and for different durations of injection. These increases in risk status were not found to differ if adjusted for OST and high coverage NSP status.
HCV treatment. Pre-2002, PWID were not recommended for HCV treatment in the United Kingdom [40] . Post-2002 , data on the number of treatments in Scotland were used to estimate the number occurring among PWID [41] . We calculated a weighted SVR rate and treatment duration based on the genotype distribution [42] [43] [44] , and assumed that only PWID on OST are treated based on current HCV treatment/care pathways in Scotland [45] .
PWID-related parameters
Injecting duration. Data on injecting cessation (1/duration) and relapse were based on the Edinburgh Addiction cohort [46, 47] .
Probability distributions were attached to all uncertain model parameters and calibration data thought to affect the decrease in HCV prevalence and incidence. Parameter values and distributions used in the model are shown in Table 1 , while calibration data from NESI are given in the Supporting information, Table S2 . More details on the model parameterization is included in the Supporting information.
Model calibration
A Bayesian model-fitting algorithm was used for model calibration. Five thousand model parameter sets were randomly sampled from the parameter uncertainty distributions in Table 1 , and 5000 HCV seroprevalence estimates for current PWID in 2008/09.
Other parameters were not sampled, but estimated for each parameter set. Through fitting reduced submodels to specific data quantities, estimates were generated for the: (1) rate PWID initiate injecting by fitting to the sampled PWID population size; (2 and 3) time-varying recruitment rates onto OST and NSP by fitting to the sampled OST and high coverage NSP coverage for specified years (1985, 2005, 2008 and 2013/14 for OST and 1990, 2008 and 2011/12 for NSP); and (4) proportion high-risk when initiating injecting and transition rates from low to highrisk by fitting to the sampled proportion high-risk for specified years (1990, 2005, 2008 and 2013/14) . See Supporting information for more detail.
These fitted parameters, along with the initially sampled parameters, were used to calibrate the full model to the sampled HCV seroprevalence among current PWID for 2008/09 by varying the overall transmission rate among PWID. These preliminary model fits to the overall HCV seroprevalence in 2008/09 were compared against the HCV seroprevalence among short-term PWID and incidence in current PWID, both from NESI in 2008/09. Any For treatment numbers, we used uncertainty range of ± 50%. As SVR varies by genotype, the average SVR was calculated using a weighted estimate based on population genotype distribution and SVR.
c
We averaged the distance from mean so we could use a normal distribution for uncertainty range. run that lay within the 95% confidence bounds for both quantities was accepted as a baseline model fit. From 5000 sampled parameter sets, 581 baseline model fits were obtained, which were used for all subsequent analyses. It is noteworthy that the baseline model fits were not calibrated to any HCV epidemiological data from later surveys, or mid-term or long-term PWID. All model fitting used the lsqnonlin algorithm in MATLAB 2016a.
Model analyses
Projections from all baseline model fits were compared against all available NESI HCV incidence estimates (2008/09, 2010, 2011/12 and 2013/14) for short-term, mid-term and long-term PWID-in total, 12 data points. This was done to assess whether the model replicated the observed decreases in these epidemiological measures while incorporating the observed scale-up of interventions and decrease in high-risk status over time. Specifically, we estimated the percentage of the 95% confidence intervals (CIs) for these 12 data points that each baseline model fit lay within, and estimated the average of this across all baseline model fits. We also generated model projections using all baseline model fits for a full counterfactual of no increase in intervention coverage (OST, NSP and HCV treatment) or decrease in high-risk behaviour post-2008, and partial counterfactuals assuming one or more of the intervention components were at constant coverage post-2008. The full and partial counterfactuals were used to estimate the number of HCV infections averted due to each intervention component, and the relative change in HCV incidence that would have occurred without any changes in intervention coverage or high-risk behaviour post-2008; 95% credibility intervals (95% CrI) were produced using the 2.5-97.5 percentile range in the projections across the model fits. Lastly, an analysis of covariance (ANCOVA) was performed on the relative decrease in incidence between 2008 and 2015 when all interventions were scaled up, and on the number of HCV infections averted during this period compared to the full counterfactual. This determined the importance of uncertainty in different parameters to the variability in these outcomes by calculating the proportion of the sum of squares contributed by each parameter [54] .
RESULTS
Model comparison with available data
The baseline 'intervention' model accurately captures the overall (Fig. 1, and by injecting Fig. 2 and Supporting information, Fig. S4 show that the model reproduces observed trends in HCV incidence from NESI between 2008 and 2014, overall and by different injecting duration categories. Indeed, on average, each baseline model fit lies within 84% (10.1/12) of the confidence bounds (95% CIs) for the 12 incidence data points against which the model was compared -none of which were fitted to. The model also, although to a lesser extent, reproduces the trends in HCV prevalence ( Fig. 2 and Supporting information, Fig. S4 ).
Impact of intervention
The model projects a mean baseline incidence of 14.2 per 100 person-years (py) (95% CrI = 9.0-20.7) among current PWID in 2008. When incorporating all changes in intervention coverage and high-risk status, the baseline 1 year) . In all graphs, black solid lines indicate the median projections for the 581 baseline 'intervention' model runs. The light grey triangles indicate the mean [whiskers are 95% confidence interval (CI)] data estimates from NESI which were fitted to and the dark grey circles indicate the mean (whiskers are 95% CI) data estimates from NESI that were not fitted to. Anti-HCV prevalence was fitted to a wider range of 49-57% 'intervention' model projects that between 2008 and 2015, HCV incidence among current PWID decreased by 61.3% (95% CrI = 45.1-75.3%) to 5.5 per 100 py (95% CrI = 2.9-9.2) ( Table 2 ). However, the counterfactual model suggests that without this intervention scale-up or change in high-risk status since 2008, HCV incidence could still have decreased (Table 2 and Fig. 3 and Supporting information, Table 2 ) occurring during that period compared to the counterfactual model. Most of the HCV infections averted (66.8%, 95% CrI = 39.9-83.7%) were due to scale-up in OST and NSP post-2008, which averted 1016 (95% CrI = 308-1996) HCV infections, whereas HCV treatment averted 72 (95% CrI = 27-137) infections (Table 2) , with the remainder (404, 95% CrI = 150-836) due to decreases in high-risk PWID.
ANCOVA analysis
ANCOVA analysis indicates that the largest contributor to the variability in the impact projections for HCV incidence came from uncertainty in the efficacy of being on both OST and NSP for reducing HCV acquisition risk (36% of the variation) and uncertainty in the efficacy of NSP alone (31% of variation). Uncertainty in the increased risk of transmission among short-term and mid-term PWID contributed 7% and 3% of the variation, respectively, whereas all other parameters contributed less than 3% (Supporting information, Fig. S5) .
Variability in the number of infections averted was mainly due to uncertainty in the turnover and size of the PWID population. Approximately 30% of the variation was due to uncertainty in the temporary cessation rate among mid-term and long-term PWID, while uncertainty in the permanent cessation rate, injecting relapse rate and PWID Projections are means of model fits, with 95% CrI in brackets. NA = not applicable; OST = opioid substitution therapy; NSP = needle and syringe programme; HCV = hepatitis C virus. 
Strengths and limitations
The strengths of our modelling are that it was developed and parameterized using detailed data on the local epidemic and intervention coverage in Scotland, and was validated through its ability to mimic the changing epidemic patterns among PWID in Scotland between 2008 and 2015, despite only being fitted to epidemiological data for 2008/09. However, limitations still exist. Firstly, the model did not simulate all epidemiological trends from the NESI surveys precisely. Model projections of HCV antibody-prevalence post-2008 tended to be lower than observed trends in Scotland. This may be due to more injectors continuing to inject than the model projected, thereby not fully capturing the long-term dynamics of injecting. Alternatively, the NESI survey may not be representative of all PWID, possibly through oversampling older PWID. Both factors could reduce the resulting observed impact of decreases in HCV incidence on reducing HCV prevalence overall, which is largely a product of population turnover. However, this would not affect the impact of intervention scale-up on more recently initiated PWID (which were simulated more accurately) where most new HCV infections occur.
Secondly, the counterfactual model also projected a decrease in HCV incidence. Supporting information, Fig. S4 shows that it agrees equally well with observed trends in HCV incidence as the intervention model, mainly due to the upturn in HCV incidence between 2011/12-2013/ 14 (NESI). This emphasizes that without strong evidence for intervention scale-up over this period, it would have been impossible to decide whether the observed decreases in HCV incidence were due to improvements in intervention coverage or other historical changes.
Thirdly, several model parameters were uncertainincluding intervention effect estimates for OST and NSP, historical OST and NSP coverage, dynamics of high-risk behaviours, cessation and relapse rates and the PWID prevalence in Scotland over time. Our projections incorporated uncertainty in all these parameters and despite this, although they were robust, they resulted in a low hit rate during the model calibration (581 of 5000 model runs were a baseline model fit). Importantly, most imprecision resulted from uncertainty in the efficacy of NSP (alongside OST or not) and factors related to PWID population turnover and size, highlighting the need for better data on these quantities.
Finally, we assume that the decrease in high-risk behaviours in PWID is independent of the scale-up in harm reduction measures and treatment. While evidence from Scotland and a recent Cochrane Review shows that OST decreases the risk of HCV acquisition through reducing the frequency of injecting, independent of this, homelessness and stimulant injecting still increase the risk of HCV transmission in Scotland, as shown in a recent pooled analysis [55] . It is possible that the increase in OST and or NSP coverage may have decreased the prevalence of high-risk behaviours, but due to a lack of data to support this it was not included as a model assumption.
Comparison with other studies
Previous modelling studies have estimated the impact of OST, NSP [8, [11] [12] [13] and HCV treatment [14, 15, 56, 57] on HCV transmission at the population level, but none have validated whether their projections are consistent with observed epidemiological data. In contrast, our model projections evaluate the evidence that increases in intervention coverage impacted upon observed population-level HCV incidence trends. Evidence from Scotland shows that these interventions are associated with decreases in HCV acquisition risk at the individual level, and that HCV incidence decreased at the population level concurrently with their scale-up [5] . However, these epidemiological analyses did not determine whether the observed decrease in incidence was consistent with the scale-up in intervention coverage; nor did they account for possible decreases in HCV transmission due to historical changes in intervention coverage and evolving epidemic dynamics. These are issues that modelling can address, as conducted in this analysis. Only one previous analysis has considered a similar question for HCV; modelling from Amsterdam showed that historical changes in risk behaviour prior to intervention scale-up contributed most to observed reductions in HCV incidence in Amsterdam [11] .
Implications and conclusions
Our model projections provide good evidence that the observed decline in HCV incidence in Scotland post-2008 was due largely to increased OST and NSP coverage, made possible through strategies implemented by the Scottish Government. These strategies provided dedicated funding for prevention [58] , and set targets for improvements in services relating to injection equipment provision, HCV treatment, and treatment for addiction.
Our model projections also highlight uncertainty in the evidence base. Further data collection is needed to better evaluate the role of NSP in decreasing HCV transmission risk, preferably from multiple studies using comparable measures of coverage or intervention intensity [7, 39] . Additionally, more linkage studies are needed to capture more effectively the natural history and transitions between injecting risk states for PWID populations [46, 59, 60] . Both these factors contributed considerable uncertainty to our projections.
This study illustrates how a country-level HCV action plan incorporating scale-up of a range of HCV prevention interventions can reduce HCV incidence markedly. This contrasts sharply with most countries where restrictions in these interventions, due to funding limitations or legal constraints [61] , severely limit their impact on HCV incidence [62] [63] [64] [65] [66] [67] . However, even with high OST and NSP coverage, the impact achieved in Scotland still falls short of the World Health Organization's strategy for reducing HCV incidence by 90% [68] , highlighting that additional interventions are required to eliminate HCV. This could include scaling-up HCV treatment, which modelling has suggested could have substantial impact [12, 56] , and the scale-up of other interventions to reduce HCV transmission, such as safe injecting facilities [69] ; expanding the use of low dead space syringes [70, 71] ; or interventions such as prison-based OST to reduce the heightened risk associated with incarceration [72, 73] . This model could be an invaluable tool for determining which of these interventions are now needed to reduce HCV transmission to elimination levels in Scotland. [2, 9] . Those used to estimate model parameters, with most varied and sampled from, are shown in bold with their distribution, whereas others (not in bold) were used to compare the model fits against to see how well the model agreed with data. Figure S1a Schematic of the injecting component of the model. The PWID population is structured into current and temporarily ceased injectors. These are further divided into short-term (<1 year since onset of injecting), midterm (1-9 years since onset) and long-term (10+ years since onset) PWID. Arrows show possible transitions from one state to another and are labelled with flow rates. New PWID enter the population as current and short-term PWID at a rate θ and leave all compartments with mortality rate μ. After one year of injecting, PWID temporarily cessate with rate p 1 and the remainder transition to the mid-term injecting compartment. PWID injecting for more than one year temporarily cessate at rate p 2 and relapse at rate p 3 . Temporarily ceased PWID that have been injecting for more than one year permanently cease injecting with rate p 4 . Figure S1b Schematic of the HCV transmission component of the model. For HCV transmission, all PWID are recruited into the susceptible uninfected population (S). After infection, a proportion of those infected with HCV spontaneously clear infection and move to the uninfected but previously infected state (anti-HCV positive -E) with the remaining proportion progressing to chronic infection (I). The chronically infected can be treated (T) -PWID that achieve a sustained viral response (SVR) move to the uninfected but previously infected class (anti-HCV positive -E) and those with a non-SVR move to the treatment failure group (F) where there is no further treatment. Superscripts indicate whether PWID are off/on OST (i=0 or 1) or off/on NSP (j=0 or 1). Subscripts indicate whether PWID are current or temporarily ceased (X=C or M), duration of injecting (Y=1,2,3 for short-term, mid-term and longterm, respectively) and high/low risk (Z=H or L). Figure S2 Figure S3 OST coverage and proportion high risk stratified by injecting duration: (a) OST coverage amongst shortterm PWID (<1 yr injecting); (b) OST coverage amongst mid-term PWID (1-9 yrs injecting); (c) OST coverage amongst long-term PWID (10+yrs injecting); (d) proportion high risk in short-term PWID (<1yr injecting); (e) proportion high risk in mid-term PWID (1-9 yrs injecting); and (f) proportion high risk in long-term PWID (10+yrs injecting). In all graphs, black solid and dashed lines indicate the median projections for the 581 baseline 'intervention' and counterfactual model runs respectively. The light grey triangles indicate the mean (whiskers are 95% CI) of the pre-NESI data, and the dark grey circles indicate the mean (whiskers are 95% CI) data estimates from NESI which were used to fit the model. Figure S4 HCV incidence per 100 person years and HCVantibody prevalence amongst PWID of different injecting durations: (a) HCV incidence amongst short-term PWID (<1 yr injecting); (b) HCV incidence amongst mid-term PWID (1-9 yrs injecting); (c) HCV incidence amongst long-term PWID (10+yrs injecting); (d) HCV antibody prevalence amongst short-term PWID (<1yr injecting); (e) HCV antibody prevalence amongst mid-term PWID (1-9 yrs injecting); and (f) HCV antibody prevalence amongst long-term PWID (10+yrs injecting). In all graphs, black solid and dashed lines indicate the median projections for the 581 baseline 'intervention' and counterfactual model runs respectively. The dark grey squares indicate the mean (whiskers are 95% CI) of the NESI data which was fit to, and the grey circles indicate the mean (whiskers are 95% CI) data estimates from NESI which were not fit to. Figure S5 ANCOVA analysis tornado plot showing model parameters which contribute >1% to variation in either the model projected decrease in incidence between 2008 and 2015 (when all interventions are scaled up) or the number of infections averted between over this period when compared to the counterfactual.
